Press release article from our research archive:

Barr Receives Tentative Approval for a Generic Version of Zofran ODT(R) Orally Disintegrating Tablets.

Barr Pharmaceuticals, Inc. today announced that Barr Laboratories, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline's Zofran ODT(R) (ondansetron) Orally Disintegrating Tablets, 4mg and 8mg. The Company anticipates receiving final approval and launching its generic product following the expiration of GlaxoSmithKline's patent on June 24, 2006 or following any additional applicable exclusivity.

Barr's Ondansetron Orally Disintegrating Tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, certain radiotherapies, and the ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!